Atopic Dermatitis
EU Partner
EU Partner
An Introduction to Atopic Dermatitis
Atopic dermatitis is a chronic skin disorder, the prevalence of which is increasing. It is caused by interactions between the epidermal barrier and immune system, with activation of multiple T cell subsets, and characterised by pruritis and cutaneous inflammation. Topical treatments include topical corticosteroids, calcineurin inhibitors, emollients and cutaneous antiseptics; severe disease requires treatment in the form of systemic immunosuppressants. Increased understanding of the pathogenesis of atopic dermatitis has led to the development of targeted therapies, such as crisaborole, a topical phosphodiesterase 4 inhibitor, and dupilumab, a subcutaneously injected interleukin-4 receptor inhibitor. Emerging therapies include Janus kinase inhibitors, aryl hydrocarbon receptor agonists, antimicrobial peptides, and biologics targeting interleukin-13, the interleukin-31 receptor, and the interleukin-5 receptor.
Our supporting partners do not constitute an endorsement of the content on this page.
Physician burnout is at a critical point. In this episode, Nicky speaks with Dr Alfred Atanda about why so many physicians are burning out and what can be done to change the trend. From personal experience to system-wide solutions, Dr Atanda shares valuable insights on improving physician well-being and building a more effective healthcare culture.
What if your medical degree could launch more than a clinical career? In this candid and compelling read, Dr Jon Edelson shares his lessons for early-career doctors ready to think beyond the bedside and explore the business of medicine.
In this episode, we explore the future of continuing medical education (CME) with the team behind touchIME. Hannah Fisher and Matthew Goodwin share insights into global and US trends, the importance of patient inclusivity and how educational outcomes are evolving to better measure the direct impact of learning on clinical practice and patient care.
Recent advancements made in understanding the pathology of inflammatory skin conditions have enabled JAK inhibitors, initially developed for haematology over 20 years ago, to be investigated for dermatological use. In this episode, Dr William (Bill) Damsky discusses JAK inhibitors’ journey from proof-of-concept to treating a wide range of skin conditions, their future impact on rare diseases and the debate around safety.
Treating moderate-to-severe atopic dermatitis in children and adolescents: Insights from the experts
Watch expert dermatologists discuss the management of moderate-to-severe AD in children and adolescents.
Watch highlights of three ADVENT symposia presented at EADV 2023
Key updates from 2 cutting-edge expert symposia presented at WCD 2023
Log into your Touch Account
Earn and track your CME credits on the go, save articles for later, and follow the latest congress coverage.
Sign up with an Email
Or use a .
This Functionality is for
Members Only
Explore the latest in medical education and stay current in your field. Create a free account to track your learning.
